A Pilot Dose Ranging Study of Spinosad Creme Rinse
Efficacy and Safety of Different Strengths of Spinosad Topical Creme (0%, 0.5%, 1.0% or 2%) in Subjects With Pediculosis Capitis - a Dose Ranging Study
2 other identifiers
interventional
36
1 country
1
Brief Summary
A pilot dose ranging study to evaluate the safety and efficacy of different strengths of Spinosad Creme versus a vehicle control.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Sep 2005
Shorter than P25 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2005
CompletedFirst Submitted
Initial submission to the registry
March 5, 2009
CompletedFirst Posted
Study publicly available on registry
March 9, 2009
CompletedOctober 20, 2015
October 1, 2015
2 months
March 5, 2009
October 19, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Efficacy of various doses of Spinosad, based on the presence or absence of live lice at 7 and 14 days post-treatment. The efficacy evaluation was performed by a trained evaluator.
14 days
Secondary Outcomes (1)
Safety of various doses of Spinosad, based on the occurrence of adverse events, especially scalp irritation.
14 days
Study Arms (4)
1
PLACEBO COMPARATORVehicle control
2
ACTIVE COMPARATOR0.5% Spinosad creme rinse
3
ACTIVE COMPARATOR1.0% Spinosad Creme Rinse
4
ACTIVE COMPARATOR2.0% Spinosad Creme Rinse
Interventions
One or two, 10-minute topical applications (7 days apart)
0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
Eligibility Criteria
You may qualify if:
- Active head lice infestation
- Male or female, 2 years of age or older
- Good general health
- Appropriately signed Informed Consent
- Subject agreement to not use any other form of lice treatment during the course of the study
- Subject agreement to not cut or chemically treat their hair between visits
You may not qualify if:
- History of irritation or sensitivity to pediculicides or hair care products
- Individuals with any visible skin/scalp condition that would interfere with the evaluation
- Individuals previously treated with a pediculicide within 4 weeks prior to study enrollment
- Individuals using hair dyes, bleaches, permanent waves or relaxing solutions 2 weeks prior to study enrollment
- Individuals who have participated in any clinical trial within 30 days of enrollment
- Individuals with family members who were infested with lice but were unwilling or unable to enroll in the study or use a standard course of lice treatment
- Females who were pregnant or nursing
- Sexually active females not using effective contraception
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- ParaPRO LLClead
Study Sites (1)
Hill Top Research
West Palm Beach, Florida, 33409, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Dyal Garg, Ph.D.
Hill Top Research
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
March 5, 2009
First Posted
March 9, 2009
Study Start
September 1, 2005
Primary Completion
November 1, 2005
Study Completion
November 1, 2005
Last Updated
October 20, 2015
Record last verified: 2015-10